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Background Surgical resection is the only curative treatment of biliary tract cancer. However, the 
prognosis of biliary tract cancer is unsatisfactory. The aim of this study was to evaluate the benefits 
of adjuvant gemcitabine chemotherapy for biliary tract cancer. 
Methods We performed a historical cohort study that involved 198 patients who underwent R0 
surgical resections. Patients who underwent major hepatectomies were administered biweekly 
intravenous gemcitabine at a dose of 800 mg/m2. Otherwise, patients were administered intravenous 
gemcitabine at a dose of 1,000 mg/m2 in 3 weekly infusions, which were followed by a 1-week 
pause. The primary outcome was overall survival. The hazard ratio of adjuvant chemotherapy was 
estimated by propensity score-stratified Cox regression that was adjusted for confounders. 
Results Forty patients received adjuvant chemotherapy. The hazard ratio of adjuvant chemotherapy 
was 0.47 (95% confidence interval, 0.28-0.95; P = 0.03). The subgroup analysis showed that the 
survival benefits were possibly modified by lymph node positivity (hazard ratio , 0.19; 95% 
confidence interval, 0.07-0.58; interaction, P = 0.22), Stage ІІІ (hazard ratio, 0.11; 95% confidence 
interval, 0.02-0.50; interaction, P < 0.01), intrahepatic cholangiocarcinoma (hazard ratio, 0.09; 95% 
confidence interval , 0.01-0.67; interaction, P = 0.05), and a poorly differentiated tumor (hazard 
ratio , 0.16; 95% confidence interval, 0.03-0.85; interaction, P = 0.13). 
Conclusions Adjuvant gemcitabine chemotherapy for biliary tract cancer may be effective, 
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particularly for patients with Stage ІІІ and intrahepatic cholangiocarcinoma. 
 
Mini-abstract 
Adjuvant gemcitabine chemotherapy for biliary tract cancer may be effective, particularly for 
patients with Stage ІІІ and intrahepatic cholangiocarcinoma. Biweekly 800 mg/m2 gemcitabine to 
patients with major hepatectomies was tolerable. 
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Introduction 
Biliary tract cancer (BTC) is a common cancer, and approximately 15,000 people have 
died of BTC in Japan in a year.1, 2 BTC was recently thought to be composed of intrahepatic 
cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma (ECC), gallbladder cancer, and 
ampulla of Vater cancer. Surgical resection is the only curative treatment of BTC. However, 60% of 
the patients with hilar cholangiocarcinomas developed distant metastasis after R0 resection.3 The 
5-year survival rate for resectable patients is around 30%.4-6 The prognosis of BTC is unsatisfactory, 
and adjuvant chemotherapy is expected to improve the long-term survival of these patients. 
Several chemotherapeutic regimens have been tested for unresectable BTC. 
Chemotherapeutic agents, such as gemcitabine (GEM), 5-fluorouracil (5-FU), oxaliplatin, and 
cisplatin (CDDP) have survival benefits for patients with advanced BTC.7-10 Among them, GEM is 
the most promising agent for BTC. We previously conducted a phase-I study in order to determine 
the maximum-tolerated dose and the recommended dose of GEM for resected BTC 
(UMIN000004682). The results of the study indicated that patients who underwent surgical 
resections for BTC could not tolerate the standard dose and schedule of GEM for unresectable BTC. 
In particular, patients who underwent major hepatectomies hardly received an administration on day 
8 because of neutropenia. 
Thus, we decided to administer biweekly intravenous GEM at a dose of 800 mg/m2 to 
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patients who underwent major hepatectomies in clinical settings. The aim of this study was to 
evaluate the survival benefits of adjuvant GEM chemotherapy for BTC. 
 
Patients and methods 
Study design and eligibility criteria 
The Kyoto University Graduate School and Faculty of Medicine Ethics Committee 
approved this study (E-1229) in accordance with the ethics guidelines for epidemiologic studies in 
Japan. We performed a historical cohort study in order to assess the survival benefits of adjuvant 
GEM chemotherapy for BTC. Patients at Kyoto University Hospital who were diagnosed with BTC 
and who underwent surgical resections between June 2001 and August 2010 were selected for this 
study. Among the 273 consecutive patients who underwent surgical resections for BTC, 211 patients 
had R0 surgical resections. The following 10 patients were excluded because they were treated with 
the following other chemotherapeutic agents in an adjuvant setting: 3 patients, Tegafur-uracil; 5 
patients, leucovorin/5-FU; and 2 patients, 5-FU/CDDP. Three patients who died in hospital after the 
surgical resections were also excluded. Thus, 198 patients were included in this study. We basically 
performed adjuvant GEM chemotherapy except for patients with Stage-І- BCT, because even the 
prognosis for the patients with stage-ІІ-BCT was unsatisfactory. 
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Adjuvant Chemotherapeutic Regimen 
 The adjuvant GEM chemotherapy was started within 12 weeks after the surgical resection. 
Before the administration of GEM, we confirmed that all drainage tubes were removed and that no 
abscesses were observed in the abdominal cavity. Patients who underwent major hepatectomies were 
treated with biweekly intravenous GEM at a dose of 800 mg/m2. Patients who did not undergo 
hepatectomies were treated with intravenous GEM at a dose of 1,000 mg/m2 in 3 weekly infusions, 
which were followed by a 1-week pause. The dose and schedule of chemotherapy was adjusted by 
individual physicians in response to the adverse events that were observed in the previous cycle. 




The primary outcome measure was overall survival (OS), which was defined as the time 
from the date of surgery to the date of death from any cause. All patients were followed until August 
2011. Patients who failed to undergo follow-up procedures were censored on the last day when they 
were confirmed to be alive.  
In the primary analysis, bias due to confounding factors was adjusted for propensity score 
stratification, which stratifies patients according to their propensity scores, the probability that a 
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patient would undergo adjuvant GEM chemotherapy. This method attempts to mimic randomization 
by creating strata of patients that received the adjuvant chemotherapy that is comparable on all 
observed confounders to strata of patients that did not receive the adjuvant chemotherapy. We 
estimated the propensity score for each patient by a multivariable logistic regression that included 
age, gender, Child–Pugh classification, primary lesion, T factor, N factor, Stage, tumor 
differentiation, operative procedures, and postoperative complications as confounders. These 
variables, other than the Child–Pugh classification, were examined after the surgical resection. The T 
factor, N factor, and Stage were estimated based on the International Union Against Cancer 
classification, 7th edition. The C statistics of the multivariate logistic regression was 0.760. The 
hazard ratios (HR) for the OS of the adjuvant chemotherapy group compared to those for the OS of 
the nonadjuvant chemotherapy group were estimated by Cox proportional hazard models that were 
stratified to the quintiles of the propensity scores. We also performed a subgroup analysis that was 
stratified for the clinical variables by using a test of the interaction terms in the Cox proportional 
hazard models, unless a stratum included less than 5 patients in either group. We used chi-square 
tests (without Yates’ correction) for the categorical comparisons of patient characteristics. The 
probability of survival was calculated by the Kaplan–Meier method. A P-value less than 0.05 
indicated statistical significance. All tests were two-tailed. JMP for Windows software ver. 8.0 and 





Forty patients received adjuvant GEM chemotherapy (the adjuvant chemotherapy group) 
and 158 patients did not receive any adjuvant chemotherapy (the nonadjuvant chemotherapy group). 
There were significant differences in age, T factor, and Stage between the groups. Patients in the 
adjuvant chemotherapy group were younger and had higher Stage of BTC. No significant differences 
were present in the primary lesion, operative procedure, or postoperative complications. The patient 
characteristics are shown in Table 1. 
Recurrence 
The probability of recurrence was 41.8% (66/158) in the nonadjuvant chemotherapy group 
and 57.5% (23/40) in the adjuvant chemotherapy group. Twenty-eight patients in the nonadjuvant 
chemotherapy group were administered GEM after tumor recurrence. The probabilities of the 1-, 2- 
and 3-year survival of the patients with recurrent BTC who were administered GEM chemotherapy 
in the nonadjuvant chemotherapy group were 88.9%, 69.8%, and 46.8%, respectively. Patients in the 
adjuvant chemotherapy tended to have a longer life expectancy without recurrence, although this 
was not significant (P = 0.16). 
Survival 
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During the follow-up period, which had a median length of 3.2 years, 13 patients in the 
adjuvant chemotherapy group and 66 patients in the nonadjuvant chemotherapy group died. The 
probabilities of 1-, 2-, and 3-year survival in the adjuvant chemotherapy group were 97.5%, 79.6%, 
and 68.0%, while those in the nonadjuvant chemotherapy group were 87.1%, 76.9%, and 68.7%, 
respectively (Figure 1). These survival probabilities were not comparable as the adjuvant 
chemotherapy group included patients with higher stages. In the propensity score analysis that was 
adjusted for the differential patient characteristics, the HR was 0.47 (95% confidence interval [CI], 
0.23-0.95; P = 0.04), suggesting a significant increase in survival by the administration of adjuvant 
GEM chemotherapy. The subgroup analysis according to the clinical variables is presented in Figure 
2. The HRs were lower in female patients (HR, 0.17; 95%CI, 0.05-0.60; interaction, P = 0.90), 
patients with ICC (HR, 0.09; 95% CI, 0.01-0.67; interaction, P = 0.05), patients with lymph node 
positivity (HR, 0.19; 95% CI, 0.07-0.58; interaction, P = 0.22), patients with Stage ІІІ BTC (HR, 
0.11; 95% CI, 0.02-0.50; interaction, P < 0.01), and patients with poorly differentiated tumors (HR, 
0.16; 95% CI, 0.03-0.85; interaction, P = 0.13). In the patients with ICC, the probability of 2-year 
survival in the adjuvant chemotherapy group was 91.7%, while that in the nonadjuvant 
chemotherapy group was 68.2% (P = 0.04). 
Adverse events 
The grade of toxicity was not estimated for 4 patients because they were not administered 
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adjuvant GEM chemotherapy at Kyoto University. Toxicities of grade 3 or more were observed in 13 
patients (13/36, 36.1%); neutropenia in 8 patients, thrombocytopenia in 2 patients, and other events 
(liver abscess, pancreatitis, vertigo) in 1 patient each. The toxicities were seen in 10 patients with 
hepatectomy (10/28, 35.7%) and 3 patients without hepatectomy (3/8, 37.5%), respectively. Two 
patients (2/36, 5.6%) had grade-4 hematological toxicities. There were no treatment-related deaths. 
 
Discussion 
A GEM-based regimen is the main chemotherapeutic agent for BTC. GEM combined with 
CDDP has recently been used as the first-line treatment for unresectable BTC in clinical practice due 
to the results of the ABC-02 trial.8 There have been few articles regarding adjuvant chemotherapy 
for BTC. Adjuvant GEM plus S-1 chemotherapy has been reported to improve outcomes after 
surgical resections of BTC.11 A phase-ІІІ trial indicated that adjuvant mitomycin C and 5-FU 
chemotherapy may have survival benefits in patients with gallbladder cancer who underwent 
noncurative resections.12 However, prospective trials have not been reported concerning adjuvant 
GEM chemotherapy. Therefore, there is no definitive regimen of adjuvant chemotherapy for BTC 
and the efficacy of the adjuvant chemotherapy has not been established. However, there have been 
several reports of adjuvant radiation and chemoradiation therapy for BTC, and some of them may be 
promising.13-15  
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In cases of adjuvant GEM chemotherapy in patients who underwent resections of 
pancreatic cancer, 62% of the patients were given the full number of cycles of intravenous GEM, 
which consisted of a dose of 1,000 mg/m2 in 3 weekly infusions, which was followed by a 1-week 
pause, for 6 cycles.16 The average weekly dose was 700 mg/m2, and the median relative-dose 
intensity was 86%.16 However, the phase-І study we previously conducted revealed that patients who 
were resected for BTC could not tolerate the standard dose. GEM is catalyzed to inactivate 
metabolite dFdU by cytidine deaminas in the liver. Patients with elevated bilirubin levels had 
significant deterioration in liver function after GEM therapy and a dose reduction is recommended.17 
We have clinically administered biweekly intravenous GEM at a dose of 800 mg/m2 to patients who 
underwent major hepatectomies. This dose reduction was well tolerated. The HR of patients with 
hepatectomies was 0.60 (95% CI, 0.28-1.29) in this study. Therefore, we think that this dose 
reduction regimen is useful for patients who underwent major hepatectomies for BTC. 
A randomized phase-III trial of adjuvant chemotherapy with GEM vs. observations in 
patients with resectable bile duct cancer (UMIN000000820) is now being conducted in Japan. This 
study is examining whether adjuvant GEM chemotherapy increases the life expectancy of patients 
with bile duct cancer. However, ICC is not included in the eligibility criteria of this study. In patients 
with ICC who underwent surgical resections, it has been reported that an aggressive approach to 
recurrence can significantly prolong survival.18 However, there is no effective adjuvant regimen for 
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ICC.19 This study indicated that adjuvant GEM chemotherapy was significantly associated with an 
increased OS of patients with ICC. It is highly expected that adjuvant GEM chemotherapy may have 
survival benefits for patients with ICC. Furthermore, previous studies have revealed that lymph node 
metastasis is an important prognostic factor in BTC.4, 6 Patients with lymph node metastasis are 
required to be treated with adjuvant therapies. The subgroup analysis showed that adjuvant GEM 
chemotherapy improved the OS of patients with lymph node positivity and patients with Stage ІІІ. 
Further assessments of the effects of adjuvant GEM chemotherapy are needed to overcome the poor 
prognosis of patients with lymph node metastasis. 
There were some limitations to this study. This study was a retrospective study, and the 
effects of adjuvant chemotherapy could not be directly evaluated, although the associations could be 
evaluated. We included postoperative complications and age in the clinical variables because they 
are thought to be related to the selection of adjuvant chemotherapy. The HR of adjuvant 
chemotherapy was estimated by a propensity score-stratified Cox regression, which was adjusted for 
confounders. However, unselected variables are not adjusted that might affect the survival benefits 
of adjuvant GEM chemotherapy. 
In conclusion, adjuvant GEM chemotherapy may be effective for patients with BCT who 
underwent R0 resection, particularly for patients with Stage ІІІ and ICC. Biweekly intravenous GEM 
at a dose of 800 mg/m2 to patients who underwent major hepatectomies was tolerable. A prospective 
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clinical trial of adjuvant GEM chemotherapy of BTC is needed to confirm these results, and it 
should be designed to include lymph node and primary lesions in addition to ICC as prescribed 
baseline factors. 
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Figure 1. Unadjusted overall survival of adjuvant gemcitabine chemotherapy compared 
to nonadjuvant chemotherapy 
Figure 2. Hazard ratio of adjuvant gemcitabine chemotherapy compared to nonadjuvant 
chemotherapy according to the clinical variables  
F i g u r e  1
Figure 2
  
Table 1. Patient characteristics 
  Nonadjuvant 
chemotherapy 
(n = 158) 
Adjuvant GEM 
chemotherapy  
(n = 40) 
P-value 
Age <75 121 (76.6) 39 (97.5) <0.01* 
 ≥75 37 (23.4) 1 (2.5)  
Gender Male 88 (55.7) 20 (50.0) 0.52 
 Female 70 (44.3) 20 (50.0)  
Child–Pugh classification A 134 (84.8) 36 (90.0) 0.39 
 B 24 (15.2) 4 (10.0)  
Primary lesion Extrahepatic 61 (38.6) 18 (45.0) 0.39 
 Intrahepatic 51 (32.3) 15 (37.5)  
 Gallbladder 30 (19.0) 6 (15.0)  
 Ampulla of Vater 16 (10.1) 1 (2.5)  
UICC T T1–2 111 (70.3) 19 (47.5) <0.01* 
 T3–4 47 (29.7) 21 (52.5)  
UICC N N0 120 (76.0) 25 (62.5) 0.09 
 N1 38 (24.0) 15 (37.5)  
UICC Stage Stage І 76 (48.1) 9 (22.5) <0.01* 
 Stage ІІ 60 (38.0) 19 (47.5)  
 Stage ІІІ 22 (13.9) 12 (30.0)  
Tumor differentiation Nonpoor 138 (87.3) 31 (77.5) 0.16 
 Poor 20 (12.7) 9 (22.5)  
Operative procedures Without Hepatectomy 47 (29.8) 10 (25.0) 0.55 
 With Hepatectomy 111 (70.2) 30 (75.0)  
Postoperative complications Yes 88 (55.7) 17 (42.5) 0.14 
 No 70 (44.3) 23 (57.5)  
UICC, International Union Against Cancer; GEM, gemcitabine 
 
